Stock Surge Draws Attention: Discussions on social media highlight Moderna's recent price breakout above key levels, with shares climbing over 20 percent in recent weeks amid strong volume. Analysts have adjusted targets upward, though consensus remains below current trading levels around 79. Observers note the move follows consolidation and positions the stock for potential further gains toward resistance zones.
Vaccine Pipeline Scrutiny: Recent federal advisory votes endorsing the mRNA flu vaccine have sparked debate, with some questioning efficacy data showing modest reductions in illness alongside elevated reaction rates. Pipeline updates on therapies like melanoma treatments also feature in conversations, underscoring ongoing development efforts. Critics emphasize gaps in long-term safety assessments for the technology.
Analyst Divergence Noted: Professional opinions range widely, from bullish channel breakouts to concerns over valuation relative to targets. Social media commentary reflects cautious optimism on technical momentum balanced against regulatory and clinical uncertainties. Overall sentiment appears mixed.
Note: This discussion summary was generated from an AI condensation of post data.
Moderna Insider Trading Activity
Moderna insiders have traded $MRNA stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:
- STEPHEN HOGE (President) has made 0 purchases and 3 sales selling 266,681 shares for an estimated $13,136,172.
- SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 17,356 shares for an estimated $899,596.
- NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
- ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Moderna Hedge Fund Activity
We have seen 336 institutional investors add shares of Moderna stock to their portfolio, and 246 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 17,626,713 shares (+62.9%) to their portfolio in Q1 2026, for an estimated $848,197,429
- CAPITAL WORLD INVESTORS added 5,869,654 shares (+45.8%) to their portfolio in Q1 2026, for an estimated $282,447,750
- BLACKROCK, INC. removed 2,869,857 shares (-8.8%) from their portfolio in Q1 2026, for an estimated $138,097,518
- GOLDMAN SACHS GROUP INC added 2,653,078 shares (+67.2%) to their portfolio in Q1 2026, for an estimated $127,666,113
- WELLINGTON MANAGEMENT GROUP LLP added 2,274,302 shares (+2730.4%) to their portfolio in Q1 2026, for an estimated $109,439,412
- TWO SIGMA INVESTMENTS, LP added 1,744,308 shares (+23.8%) to their portfolio in Q1 2026, for an estimated $83,936,100
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 1,560,559 shares (-96.6%) from their portfolio in Q1 2026, for an estimated $75,094,099
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Moderna Analyst Ratings
Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/23/2026
To track analyst ratings and price targets for Moderna, check out Quiver Quantitative's $MRNA forecast page.
Moderna Price Targets
Multiple analysts have issued price targets for $MRNA recently. We have seen 7 analysts offer price targets for $MRNA in the last 6 months, with a median target of $48.0.
Here are some recent targets:
- Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026
- Dimple Gosai from B of A Securities set a target price of $34.0 on 06/08/2026
- Luca Issi from RBC Capital set a target price of $38.0 on 05/04/2026
- Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
- Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
- Eliana Merle from UBS set a target price of $45.0 on 05/04/2026
- Eliana Merle from Barclays set a target price of $48.0 on 04/02/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
